<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500212</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-06235AA1-02</org_study_id>
    <secondary_id>2014-005572-28</secondary_id>
    <nct_id>NCT02500212</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients</brief_title>
  <official_title>OPEN-LABEL, MULTICENTRE, RANDOMIZED CLINICAL TRIAL TO COMPARE THE PHARMACOKINETICS OF ENVARSUS® TABLETS AND ADVAGRAF® CAPSULES ADMINISTERED ONCE DAILY IN ADULT DE-NOVO KIDNEY TRANSPLANT PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, multicentre, randomized clinical trial to compare the pharmacokinetics of
      ENVARSUS® tablets and ADVAGRAF® capsules administered once daily in adult de-novo kidney
      transplant patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tacrolimus Area under the curve (AUC 0-24h)r h*pg/mL</measure>
    <time_frame>pre-dose, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 12.0, 16.0, 20.0, 24.0 hr post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus concentration 24 hours post-dose (C24hr) pg/mL</measure>
    <time_frame>24.0 hr post-dose</time_frame>
    <description>Whole blood trough drug concentration 24hour post dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine (mg/dL)</measure>
    <time_frame>before dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate (eGFR) mL/min;</measure>
    <time_frame>before dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate, (beats per minute)</measure>
    <time_frame>before dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qt (milliseconds)</measure>
    <time_frame>before dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Organ or Tissue Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>ENVARSUS tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Envarsus® (tacrolimus) prolonged-release tablets provided in 0.75 mg, 1.0 mg and 4.0 mg dose strengths.
Envarsus® tablets will be administered orally once daily in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ADVAGRAF capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Advagraf® (tacrolimus) prolonged-release hard capsules provided in 0.5 mg, 1.0 mg, 3.0 mg and 5.0 mg dose strengths.
Advagraf® capsules will be administered orally once daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENVARSUS®</intervention_name>
    <arm_group_label>ENVARSUS tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADVAGRAF®</intervention_name>
    <arm_group_label>ADVAGRAF capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipients of a kidney transplant from a deceased donor or a living donor

        Exclusion Criteria:

          -  Recipient of any transplanted organ other than a kidney;

          -  Recipients of a bone marrow or stem cell transplant;

          -  Recipients of a kidney from a cardiac death donor;

          -  Recipients of a kidney from an ABO incompatible donor;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nephrology Department Hopital La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>296009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Nephrologie CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Nephrologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité de transplantation rénale -Hopital Pasteur</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology department CHU de Saint-Etienne Hospital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil, 1 avenue J Poulhes TSA 50032.</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-005572-28</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

